Human acetyltransferase polymorphism

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 376, Issue 1-2, 1997, Pages 61-70

  Grant, Denis M ^a   Hughes, Nicola C ^a   Janezic, Susan A ^a   Goodfellow, Geoffrey H ^a   Chen, Hillary J ^a   Gaedigk, Andrea ^a   Yu, Violeta L ^a   Grewal, Ranbir ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Acetylation; Acetyltransferase; Arylamine carcinogen; Metabolic activation; Pharmacogenetics; Polymorphism

Indexed keywords

ACYLTRANSFERASE; AROMATIC AMINE; CARCINOGEN; HETEROCYCLIC AMINE; ISONIAZID; SULFADIMIDINE; AMINE; AMINOSALICYLIC ACID; ARYLAMINE ACETYLTRANSFERASE; ISOENZYME; NAT2 PROTEIN, HUMAN;

ACETYLATION; ARTICLE; CANCER RISK; DETOXIFICATION; GENETIC POLYMORPHISM; HUMAN; METABOLIC ACTIVATION; PHARMACOGENETICS; PRIORITY JOURNAL; ALLELE; BIOTRANSFORMATION; GENE; GENETICS; KINETICS; METABOLISM; RACE;

ACETYLATION; ALLELES; AMINES; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CONTINENTAL POPULATION GROUPS; GENES; HUMANS; ISOENZYMES; KINETICS; P-AMINOSALICYLIC ACID; POLYMORPHISM, GENETIC;

EID: 0031011356     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00026-2     Document Type: Article

References (47)

1. Aune, T., R.R. Vanderslice, J.E. Croft, E. Dybing, J.R. Bend and R.M. Philpot (1985) Cancer Res., 45, 5859-5866.
2. Badawi, A.F., A. Hirvonen, D.A. Bell, N.P. Lang and F.F. Kadlubar (1995) Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder, Cancer Res., 55, 5230-5237.
3. Bell, D.A., J.A. Taylor, M.A. Butler, E.A. Stephens, J. Wiest, L.H. Brubaker, F.F. Kadlubar and G.W. Lucier (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans, Carcinogenesis, 14, 1689-1692.
4. Bell, D.A., A.F. Badawi, N.P. Lang, K.F. Ilett, F.F. Kadlubar and A. Hirvonen (1995a) Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue, Cancer Res., 55, 5226-5229.
5. Bell, D.A., E.A. Stephens, T. Castranio, D.M. Umbach, M. Watson, M. Deakin, J. Elder, C. Hendrickse, H. Duncan and R.C. Strange (1995b) Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer, Cancer Res., 55, 3537-3542.
6. Blum, M., D.M. Grant, O.W. McBride, M. Heim and U.A. Meyer (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression, DNA Cell Biol., 9, 193-203.
7. Blum, M., A. Demierre, D.M. Grant, M. Heim and U.A. Meyer (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans, Proc. Nat. Acad. Sci. (USA), 88, 5237-5241.
8. Boteju, L.W. and P.E. Hanna (1994) Arylamine-nucleoside adduct formation: evidence for arylnitrene involvement in the reactions of an N-acetoxyarylamine, Chem. Res. Toxicol., 7, 684-689.
9. Cartwright, R.A., H.J. Rogers, D. Barham-Hall, R.W. Glashan, R.A. Ahmad, E. Higgins and M.A. Kahn (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer, Lancet, 2, 842-846.
10. Chou, H.-C., N.P. Lang and F.F. Kadlubar (1995) Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s), Cancer Res., 55, 525-529.
11. Cribb, A.E., D.M. Grant, M.A. Miller and S.P. Spielberg (1991) Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes, J. Pharmacol. Exp. Ther., 259, 1241-1246.
12. Deguchi, T., M. Mashimo and T. Suzuki (1990) Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver, J. Biol. Chem., 265, 12757-12760.
13. Deloménie, C., D.M. Grant, P. Mathelier-Fusade, C. Jacomet, F. Leynadier, E. Jacqz-Aigrain, W. Rozenbaum, R. Krishnamoorthy and J.-M. Dupret (1994) N-acetylation genotype and risk of severe reactions to sulfonamides in AIDS patients, Br. J. Clin. Pharmac., 38, 581-582.
14. Deloménie, C., L. Sica, D.M. Grant, R. Krishnamoorthy and J.-M. Dupret (1996) Genotyping of the polymorphic N-acetyltransferase (NAT2) gene locus in two native African populations, Pharmacogenetics, 6, 177-185.
15. 68 in the catalytic mechanism of polymorphic human NAT2, J. Biol. Chem., 267, 7381-7385.
16. Eling, T.E. and J.F. Curtis (1992) Xenobiotic metabolism by prostaglandin H synthase, Pharmacol. Ther., 53, 261-273.
17. Evans, D.A. (1992) N-acetyltransferase, in: W. Kalow (Ed.), Pharmacogenetics of Drug Metabolism, Pergamon Press, New York, pp. 95-178.
18. Grant, D.M., K. Mörike, M. Eichelbaum and U.A. Meyer (1990) Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver, J. Clin. Invest., 85, 968-972.
19. Grant, D.M., M. Blum, M. Beer and U.A. Meyer (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes, Mol. Pharmacol., 39, 184-191.
20. Grant, D.M. and U.A. Meyer (1993) Arylamine N-acetyltransferase, in: A. Haeberli (Ed.), Human Protein Data, VCH Verlagsges., Weinheim.
21. Grant, D.M., D.A. Bell and R. Grewal (1994) Functional analysis of variant alleles of human arylamine acetyltransferase NAT2 by heterologous expression in E. coli, 10th International Symposium on Microsomes and Drug Oxidations, Toronto, Canada, p. 259.
22. Guengerich, F.P. (1992) Metabolic activation of carcinogens, Pharmacol. Ther., 54, 17-61.
23. Hein, D.W. (1988) Acetylator genotype and arylamine-induced carcinogenesis, Biochim. Biophys. Acta, 948, 37-66.
24. Hein, D.W., M.A. Doll, T.D. Rustan, K. Gray, Y. Feng, R.J. Ferguson and D.M. Grant (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases, Carcinogenesis, 14, 1633-1638.
25. Hein, D.W., R.J. Ferguson, M.A. Doll, T.D. Rustan and K. Gray (1994) Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes, Hum. Mol. Genet., 3, 729-734.
26. Hickman, D. and E. Sim (1991) N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans, Biochem. Pharmacol., 42, 1007-1014.
27. Hickman, D., J.R. Palamanda, J.D. Unadkat and E. Sim (1995) Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli, Biochem. Pharmacol., 50, 697-703.
28. Hughes, N.C., K.L. McQueen, S.A. Janezic, M.A.S. Jewett and D.M. Grant (1997) Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in vivo/in vitro probe, Pharmacogenetics, 7, in press.
29. Kalow, W. and D.M. Grant (1995a) Genetic variation of drug metabolizing enzymes, in: G.M. Pacifici and G.N. Fracchia (Eds.), Advances in Drug Metabolism in Man, European Commission DG XII - Science, Research and Development, Brussels, pp. 57-84.
30. Kalow, W. and D.M. Grant (1995b) Pharmacogenetics, in: C. Scriver, A. Beaudet, W. Sly and D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, 7th Edition, McGraw-Hill Inc, New York, pp. 293-326.
31. Ladero, J.M., J.F. Gonzalez, J. Benitez, E. Vargas, M.J. Fernandez, W. Baki and M. Diaz-Rubio (1991) Acetylator polymorphism in human colorectal carcinoma, Cancer Res., 51, 2098-2100.
32. Lang, N.P., D.Z.J. Chu, C.F. Hunter, D.C. Kendall, T.J. Flammang and F.F. Kadlubar (1986) Role of aromatic amine acetyltransferase in human colorectal cancer, Arch. Surg., 121, 1259-1261.
33. Lee, B.L., D. Wong, N.L. Benowitz and P.M. Sullam (1993) Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome, Clin. Pharmacol. Ther., 53, 529-535.
34. Lin, H.J., C.Y. Han, B.K. Lin and S. Hardy (1993) Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 asians, blacks, hispanics, and whites - application to metabolic epidemiology, Am. J. Hum. Genet., 52, 827-834.
35. Meyer, U.A. (1995) Molecular genetics of the acetyltransferases, in: G.M. Pacifici and G.N. Fracchia (Eds.), Advances in Drug Metabolism in Man, European Commission DG XII - Science, Research and Development, Brussels, pp. 587-606.
36. Ohsako, S. and T. Deguchi (1990) Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver, J. Biol. Chem., 265, 4630-4634.
37. Orzechowski, A., D. Schrenk, B.S. Bock-Hennig and K.W. Bock (1994) Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human UDP-glucuronosyltransferases of the UGT1 gene complex, Carcinogenesis, 15, 1549-1553.
38. Probst-Hensch, N.M., R.W. Haile, S.A. Ingles, M.P. Longnecker, C.Y. Han, B.K. Lin, D.B. Lee, G.T. Sakamoto, H.D. Frankl and E.R. Lee (1995) Acetylation polymorphism and prevalence of colorectal adenomas, Cancer Res., 55, 2017-2020.
39. Risch, A., D.M. Wallace, S. Bathers and E. Sim (1995) Slow N-acetylation genotype is a susceptibility factor in occupational and smoking-related bladder cancer, Hum. Mol. Genet., 4, 231-236.
40. Shear, N.H., S.P. Spielberg, D.M. Grant, B.K. Tang and W. Kalow (1986) Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity, Ann. Intern. Med., 105, 179-184.
41. Taylor, J.A., D. Umbach, E. Stephens, D. Paulson, C. Robertson, J.L. Mohler and D.A. Bell (1995) Role of N-acetylation polymorphism at NAT1 and NAT2 in smoking-associated bladder cancer, Proc. Am. Assoc. Cancer Res., 36, 282.
42. Vatsis, K.P., K.J. Martell and W.W. Weber (1991) Diverse point mutations in the human gene for polymorphic N-acetyltransferase, Proc. Nat. Acad. Sci. USA, 88, 6333-6337.
43. Vatsis, K.P. and W.W. Weber (1993) Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus, Arch. Biochem. Biophys., 301, 71-76.
44. Vatsis, K.P., Y. Yao and W.W. Weber (1994) Allelic variation at the NAT1 locus of N-acetyltransferase among Orientals, Am. J. Hum. Genet., 55 (Suppl), A340.
45. Vatsis, K.P., W.W. Weber, D.A. Bell, J.-M. Dupret, D.A. Price Evans, D.M. Grant, D.W. Hein, H.J. Lin, U.A. Meyer, M.V. Relling, E. Sim, T. Suzuki and Y. Yamazoe (1995) Nomenclature for N-acetyltransferases, Pharmacogenetics, 5, 1-17.
46. Weber, W.W. and K.P. Vatsis (1995) Human N-acetyltransferases: genetic polymorphism and metabolic profiles of the major isoforms, in: G.M. Pacifici and G.N. Fracchia (Eds.), Advances in Drug Metabolism in Man, European Commission DG XII - Science, Research and Development, Brussels, pp. 351-405.
47. Wolkenstein, P., V. Carriere, D. Charue, S. Bastuji-Garin, J. Revuz, J.-C. Roujeau, P. Beaune and M. Bagot (1995) A slow acetylator genotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome, Pharmacogenetics, 5, 255-258.